Itopride

Oral
Disorders associated with reduced gastrointestinal motility
Adult: For the management of gastrointestinal symptoms including the feeling of swollen abdomen, early satiety, postprandial fullness, upper abdominal pain or discomfort, nausea and vomiting, anorexia, and heartburn; non-ulcer dyspepsia: 50 mg tid. May reduce dose depending on the patient's age and symptoms.

Conditions when increased gastrointestinal motility may be harmful (e.g. gastrointestinal haemorrhage, mechanical obstruction or perforation).

Elderly. Pregnancy and lactation.

Significant: May cause cholinergic effects. Gastrointestinal disorders: Abdominal pain, diarrhoea, salivary hypersecretion. Investigations: Increased ALT, decreased WBC count. Nervous system disorders: Dizziness, headache. Skin and subcutaneous tissue disorders: Rash.

May reduce activity with anticholinergic agents.

Itopride is a gastroprokinetic agent. It increases acetylcholine concentrations by antagonising dopamine D₂ receptors and inhibiting acetylcholinesterase, thereby promoting gastrointestinal motility.
Absorption: Rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability: 60%. Time to peak plasma concentration: 0.5-0.75 hours.
Distribution: Plasma protein binding: Approx 96%, mainly to albumin.
Metabolism: Extensively metabolised in the liver mainly via flavine monooxygenase enzymes.
Excretion: Via urine. Terminal elimination half-life: Approx 6 hours.

Oral: Store below 30°C. Protect from light and moisture.

GIT Regulators, Antiflatulents & Anti-Inflammatories

A03FA07 - itopride ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.